PLAY PODCASTS
LTR 143: Jennifer Mascioli-Tudor on Leading Proactive Quality in the QMSR Era

LTR 143: Jennifer Mascioli-Tudor on Leading Proactive Quality in the QMSR Era

Let's Talk Risk! with Dr. Naveen Agarwal · Naveen Agarwal, Ph.D.

February 13, 202630m 32s

Audio is streamed directly from the publisher (api.substack.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Summary

“Management review is no longer a check-the-box exercise. It’s the most powerful lever leaders have to drive proactive quality.”

In this episode of the Let’s Talk Risk Podcast, Naveen Agarwal sits down with Jennifer Mascioli-Tudor, an experienced Quality and Regulatory leader, to unpack what QMSR readiness really means in practice.

Jennifer shares what she’s seeing across the industry, from companies that are fully prepared to those that haven’t started, and explains why being ISO 13485 certified is not enough. The conversation dives deep into FDA inspection behavior, closed-loop risk management, management review as a leadership tool (not a formality), and the very real consequences of reactive quality systems.

This episode is a must-listen for quality, regulatory, and executive leaders who want to move beyond compliance and build proactive, inspection-ready organizations.

Chapters

00:00 Welcome and Introduction02:20 ISO 13485 vs FDA inspections: where assumptions break down03:40 Closed-loop risk management across the total product lifecycle05:40 How FDA uses complaints, CAPA, and trends to escalate inspections09:35 Leadership mindset shift: from reactive fixes to proactive quality11:35 Management review as a strategic decision-making forum20:25 Inspection readiness as culture, practice, and people, not paperwork

If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.

Suggested links:

* LTR: QMSR Readiness, Risk-Based Assurance and FDA Expectations.

* LTR: 90-Day QMSR Readiness Action Pan for Leaders.

* LTR: FDA Readiness for QMSR.

Key Takeaways

* Don’t wait for FDA to expose your gaps, identify and document them yourself

* Treat QMSR as a strategic initiative, not a quality department project

* Use management review to drive real discussion, decisions, and accountability

* Focus on the critical few metrics, not dozens of unprioritized indicators

* Train SMEs and cross-functional leaders to speak confidently about risk

* Practice inspection scenarios before FDA shows up, not during the inspection

Keywords

QMSR, FDA inspection readiness, closed-loop risk management, ISO 13485, management review, risk-based decision making, proactive quality, trend escalation, cross-functional accountability, total product lifecycle

About Jennifer Mascioli-Tudor

Jennifer Mascioli-Tudor is currently the Founder and Principal Consultant at JMT Compliance Consulting offering consultant services to MedTech organizations in business, regulatory and quality management strategy. She is also an instructor at UC San Diego where she teaches regulatory fundamentals and design controls. Her industry experience includes leadership roles at J&J, Boston Scientific, Medtronic, and GE Healthcare. She holds a BSc from Eastern Michigan University, an MBA in Global Management, and is an ASQ Certified Quality Auditor.

Disclaimer

Information and insights presented in this podcast are for educational purposes only. Views expressed by all speakers are their own and do not reflect those of their respective organizations.

Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards.



This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe